Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS

NEXT STORY
Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community
PREV STORY
OncXerna Therapeutics Announces New Phase 2 and Biomarker Data in Gastric Cancer from Bavituximab Program at the ESMO Congress 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Merus Announces Participation in Four Investor Conferences in February 2018

UTRECHT, The Netherlands, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage ...

author_avatar
NASDAQ Market News

RedHill Biopharma Provides 2017 Year-End Business Update

TEL-AVIV, Israel and RALEIGH, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ...

author_avatar
NASDAQ Market News

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

Novartis to focus Sandoz division in US on higher growth areas and will sell ...

author_avatar
NASDAQ Market News